A phase II study of carboplatin and etopside plus durvalumab for previously-untreated extensive-stage small-cell lung cancer (ES-ECLC) patients with poor performance status (PS) - NEJ045A

开始日期2021-04-08

申办/合作机构-

ChiCTR2000041332 / Recruiting早期临床1期IIT

A Study of Camrelizumab, Etopside and Cisplatin Combined Radiotherapy in the Treatment of Patients with Limited Stage Small Cell Lung Cancer (SCLC)

开始日期2020-12-31

申办/合作机构

北京市肿瘤防治研究所

NCT02911142 / Active, not recruiting临床1/2期IIT

Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma

Background:
Primary effusion lymphoma (PEL) is a rare disease with no standard treatment. Researchers want to see if a drug called lenalidomide along with common chemotherapy drugs may be effective in treating PEL.
Objective:
To test a new treatment for PEL.
Eligibility:
People ages 18 and older with PEL.
Design:
Participants will be screened with blood tests, imaging studies, a physical exam, and other tests.
Participants will have tests to evaluate their disease. These may include:
Blood tests
Scans
Lumbar puncture. Fluid around the spinal cord will be removed with a needle.
Bone marrow removed with a needle and studied
Samples of skin or lymph nodes removed
Fluid removed from around organs
Lung and eye tests
Tubes with cameras taking pictures of airways or digestive tract
Participants will take lenalidomide pills for 10 days. They will keep a pill diary.
Participants will have a catheter (small tube) placed in the large vein in the arm or chest.
Participants will get DA-EPOCH-R as intravenous infusions by catheter over several days. This will be repeated in 21-day cycles. Most participants will have 6 cycles.
Participants will get the drug filgrastim by injection under the skin. They will get the drug methotrexate injected into the spinal fluid.
During the study, participants will have the following tests done at least once:
Medical history
Physical exam
Blood, urine, and stool tests
Lesions photographed and measured
Lumbar puncture
Participants will have follow-up visits for 5 years. They will repeat the screening tests plus have urine and stool tested.
Participants may be contacted later by phone to see how they are doing.

开始日期2017-07-03

申办/合作机构

National Cancer Institute

100 项与足叶乙甙相关的临床结果

登录后查看更多信息

100 项与足叶乙甙相关的转化医学

登录后查看更多信息

100 项与足叶乙甙相关的专利（医药）

登录后查看更多信息

项与足叶乙甙相关的文献（医药）

2023-04-01·Tissue and Cell

Rosemary (Rosmarinus officinalis L.) essential oil alleviates testis failure induced by Etoposide in male rats

Article

作者: Saied, Mohammadzadeh ; Ali, Kiani ; Mosayeb, Amiri

Rosemary (Rosmarinus officinalis L.) is a shrub used to treat hepatic, intestinal, renal, respiratory, and reproductive failures. Etoposide a plant-based compound derived from Podophyllum pelltatum, has been used for human malignancies treatment. However, it induces testis, and hepatic failures. In the present study, impact of rosemary essential oil against testis failure, lipid parameters, and hepatic enzymes in male rats has been studied. Forty male Wistar albino rats were grouped in a completely randomized design with Etoposide injection (ETO), rosemary supplementation (ROS), with Etoposide injection and rosemary supplement (ETO+ROS), and control rats with no Etoposide injection and no rosemary (CON). The experiment lasted for seven consecutive weeks including one week as acclimatization time. At the end of the experiment, rats were sacrificed by cervical dislocation, and blood samples were analyzed for serum alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG), low-density lipoprotein-Cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), total cholesterol (TC), total Protein (TP), glucose (GLU) and testosterone. The left testis was harvested for histological examination. Results showed that rats with Etoposide injection had higher ALT, AST, and ALP the control rats. No significant difference was found among treatments in terms of glucose concentration in blood. Rosemary supplemntaion decreased cholesterol and TG concentration and increased HDL concentration in male rats. Furthermore, administration of rosemary essential oil increased blood testosterone but decreased ALT and AST. The epithelial height of seminiferous tubules was decreased significantly in ET as compared with CON. Rosemary essential oil lessened the adverse effect of Etopside on epithelial height in rat testis as it is shown in ET+ROS. In conclusion, dietary supplementation of rosemary essential oil alleviated liver toxicity and functional testis damage induced by Etopside.

2022-09-16·Medicine

Apatinib and temozolomide in children with recurrent ependymoma: A case report

Article

作者: Shi, Lei ; Shen, Zhipeng ; Li, Juan ; Zhang, Ni ; Zhao, Shuangshuang

Rationale:Outcomes remain poor in children with recurrent ependyomams (rEPNs), despite advances in surgery and radiotherapy. Systemic therapeutic options are limited, given the low response to chemotherapy and targeted drugs. There is an urgent need for efective pharmacotherapy. Apatinib is a multitarget tyrosine kinase inhibitor, which has been reported to exhibit broad antitumor profiles. However, its effects on rEPNs have not been reported thus far.Patient concerns:We present a 5-year-old recurrent ependyomam patient benefting from apatinib and temozolomide. The patient was diagnosed with ependyomam in January 2016 and treated with surgery and radiotherapy. After surgery, the patient walked with an mild unsteady gait. He was diagnosed with recurrence in November 2018 following which he was treated with reoperation, reirradiation and chemotherapy (etopside, cisplatin, and temozolomide [TMZ]). The patients increased gait instability in April 2019.Diagnoses:Magnetic resonance imaging (MRI) showed progression of the disease. The lession at the left edge of the fourth ventricle and cerebellar peduncles was significantly increased.Interventions:The patient was administer TMZ (200 mg/m2/d, d1-5, 28 days as a cycle) + apatinib (250 mg, every other day). Twelve cycle of TMZ and apatinib were given.Outcomes:The tumor significantly shrank during the patient received TMZ and apatinib. After 9 months of medication, MRI revealed a nearly complete response However, the tumor progressed on May 5, 2020. From the beginning of the application of TMZ and apatinib, the progression-free survival was 1 year and the survival time was 19 months. Grade 1 leukocytopenia was observed without other adverse effects.Conclusion:Apatinib and temozolomide treatment with mild side effects may be a new option for children with recurrent ependyomams.

2022-01-01·Journal of Cancer Research and Therapeutics4区 · 医学

Clinical response of carboplatin-based chemotherapy and its association to genetic polymorphism in lung cancer patients from North India – A clinical pharmacogenomics study

4区 · 医学

Article

作者: Kumar, Munish ; Ritambhara ; Vijayaraghavalu, Sivakumar ; Tiwari, Sonia ; Al-Khedhairy, Abdulaziz A ; Siddiqui, Maqsood A

Purpose:Lung cancer mostly diagnosed at advanced inoperable stages; thereby, the chemo-, radiation-, targeted or immune-therapy alone or in combination remains the treatment of choice. In chemotherapy, platinum-based compounds such as cisplatin and carboplatin and third-generation drugs such as docetaxel, paclitaxel, gemcitabine, and vinorelbine are widely used. The beneficial therapeutic outcome of the chemotherapy alone or in combination with radiation (chemoradiation) and/or development of drug resistance depends on the inter-individual genetic differences. Hence, this study was carried out to find gene biomarker that could be useful in the diagnosis of the disease and to predict the outcome of chemo/chemoradiation therapy in ethnic North Indian population.Materials and Methods:In this clinical study, lung cancer (n = 52) patients from North Indian population were recruited. All the patients were treated with carboplatin target area under curve-5 in combination with third-generation drugs (gemcitabine 1.2 mg/m2; paclitaxel 175 mg/m2; and etopside 100 mg/m2) and radiation therapy. The genomic DNA was isolated from the blood sample and performed polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism.Results:We found hazard ratio to be significantly higher for XPDLys751Gln (hazard ratio [HR] =2.11, 95% confidence interval [CI]: 0.98–4.53, P = 0.056) and IL1 β511C/T (HR = 9.9, 95% CI: 2.55–38.40, P = 0.001). GSTT1 null (HR = 0.39, 95%CI: 0.18-0.84, P = 0.017) genotype has better response to chemotherapy. Generalized multidimensional reduction model suggested that IL1RN (cross-validation consistency [CVC] =10/10, P = 0.054) and XRCC1399Gln, GSTM1 (CVC = 10/10, P = 0.001) as best predicted model in lung cancer patients to the treatment response.Conclusion:Genetic polymorphisms and single nucleotide polymorphisms in DNA repair gene (XRCC1, XPD) and drug-metabolizing gene (GSTM1 and GSTT1) could serve as genetic biomarkers in lung cancer patients treated with the above indicated chemotherapy. Based on genotype and chemotherapy treatments, the toxicity effects can be minimized, this will help in the development of personalized medicine in future with better efficacy.

100 项与足叶乙甙相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
艾滋病相关性淋巴瘤	临床2期	美国	National Cancer Institute	2017-07-03
伯基特淋巴瘤	临床2期	美国	National Cancer Institute	2017-07-03
弥漫性大B细胞淋巴瘤	临床2期	美国	National Cancer Institute	2017-07-03
多中心Castleman病	临床2期	美国	National Cancer Institute	2017-07-03